A meta-analysis of five clinical trials on neoadjuvant EGFR-TKIs indicated that patients with EGFR-mutated stage IIIA NSCLC were extremely sensitive to neoadjuvant EGFR-TKI, and the incidence of grade 3/4 AEs in the targeted therapy group was significantly lower than that in the neoadjuvant chemotherapy group (26). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.